Notice type: 3rd Party Publications
Date: 24/04/2019
Important Safety Information communication from Sanofi Genzyme on Lemtrada (alemtuzumab): Restriction of use due to serious safety concerns
Important Safety Information - Lemtrada (alemtuzumab)